
Keywords: prostatic neoplasms; antiandrogens; cardiovascular diseases; diabetes mellitus; riskADT, androgen deprivation therapy; CVD, cardiovascular disease; DM, diabetes; PCOS, Prostate Cancer Outcomes Study; PSA, prostate specific antigen; SEER, Surveillance, Epi